Blood Adv Blood advances, 5(4), 1110-1121. American Society of Hematology Blood advances Blood, 5(4), 1110-1121. American Society of Hematology Löwenberg, B, Pabst, T, Maertens, J, Gradowska, P, Biemond, B J, Spertini, O, Vellenga, E, Griskevicius, L, Tick, L W, Jongen-Lavrencic, M, Kooy, M V M, Vekemans, M-C, van der Velden, W J F M, Beverloo, B, Michaux, L, Graux, C, Deeren, D, Weerdt, O D, Esser, J W J V, Klein, M B S K, Gadisseur, A, Westerweel, P E, Veelken, H, Gregor, M, Silzle, T, Lammeren-Venema, D Ë V, Moors, I, Breems, D A, Hoogendoorn, M, Legdeur, M-C J C, Fischer, T, Kuball, J, Porkka, J C K, Juliusson, G, Meyer, P, Höglund, M, Gjertsen, B T, Janssen, J J W M, Huls, G, Passweg, J, Cloos, J, Valk, P J M, Elssen, C H M J V, Manz, M G, Floisand, Y & Ossenkoppele, G J 2021, ' Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: The HOVON-SAKK-132 trial ', Blood, vol. 5, no. 4, pp. 1110-1121 . https://doi.org/10.1182/bloodadvances.2020003855 BLOOD ADVANCES Blood Advances, 5(4), 1110-1121. AMER SOC HEMATOLOGY Blood Advances, 5, 1110-1121 Blood advances, 5(4), 1110-1121. The American Society of Hematology Blood advances, Vol. 5, no. 4, p. 1110-1121 (2021) Blood Advances, 5, 4, pp. 1110-1121 Blood, 5(4), 1110-1121. AMER SOC HEMATOLOGY Blood advances, Washington : American Society of Hematology, 2021, vol. 5, no. 4, p. 1110-1121